KR880001630A - 5-fluorouracil derivatives and uses thereof - Google Patents

5-fluorouracil derivatives and uses thereof Download PDF

Info

Publication number
KR880001630A
KR880001630A KR1019870006895A KR870006895A KR880001630A KR 880001630 A KR880001630 A KR 880001630A KR 1019870006895 A KR1019870006895 A KR 1019870006895A KR 870006895 A KR870006895 A KR 870006895A KR 880001630 A KR880001630 A KR 880001630A
Authority
KR
South Korea
Prior art keywords
fluorouracil
fluorouracil derivative
pyridyloxycarbonyl
benzoyloxy
ethoxymethyl
Prior art date
Application number
KR1019870006895A
Other languages
Korean (ko)
Other versions
KR950011394B1 (en
Inventor
세쓰로 후지이
Original Assignee
오오쓰까 아끼히꼬
오오쓰까세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP61181027A external-priority patent/JPS63301880A/en
Priority claimed from JP62034161A external-priority patent/JPS63201127A/en
Application filed by 오오쓰까 아끼히꼬, 오오쓰까세이야꾸 가부시끼가이샤 filed Critical 오오쓰까 아끼히꼬
Publication of KR880001630A publication Critical patent/KR880001630A/en
Application granted granted Critical
Publication of KR950011394B1 publication Critical patent/KR950011394B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음No content

Description

5-플루오로우라실 유도체 및 그의 용도5-fluorouracil derivatives and uses thereof

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (10)

하기 일반식(I)로 표시되는 5-플루오로우라실 유도체.5-Fluorouracil derivatives represented by the following general formula (I). [상기 식중, Ra는 C1~C6알콕시메틸기이다].[Wherein R a is a C 1 to C 6 alkoxymethyl group]. 제1항에 있어서, 5-플루오로우라실 유도체가 3-[3-(6-벤조일옥시-3-시아노-2-피리딜옥시카르보닐)벤조일]-1-에톡시메틸-5-플루오로우라실인 화합물.The compound of claim 1, wherein the 5-fluorouracil derivative is 3- [3- (6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl) benzoyl] -1-ethoxymethyl-5-fluoro A compound that is uracil. 하기 일반식(I)로 표시되는 5-플루오로우라실 유도체의 유효량 및 약학적으로 허용 가능한 담체로 구성되는 항암 조성물.An anticancer composition comprising an effective amount of a 5-fluorouracil derivative represented by the following general formula (I) and a pharmaceutically acceptable carrier. [상기 식중, Ra는 C1~C6알콕시메틸기이다].[Wherein R a is a C 1 to C 6 alkoxymethyl group]. 제3항에 있어서, 5-플루오로우라실 유도체가 3-[3-(6-벤조일옥시-3-시아노-2-피리딜옥시카르보닐) 벤조일]-1-에톡시메틸-5-플루오로우라실인 항암 조성물.The 5-fluorouracil derivative according to claim 3, wherein the 5-fluorouracil derivative is 3- [3- (6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl) benzoyl] -1-ethoxymethyl-5-fluoro An anticancer composition that is uracil. 하기 일반식(1)로 표시되는 5-플루오로우라실 유도체의 유효량을 환자에게 투여함을 특징으로 하는 환자에 있어서 암의 치료방법.A method for treating cancer in a patient, characterized by administering to the patient an effective amount of the 5-fluorouracil derivative represented by the following general formula (1). [상기 식중, Ra는 C1~C6알콕시메틸기이다].[Wherein R a is a C 1 to C 6 alkoxymethyl group]. 제5항에 있어서, 5-플루오로우라실 유도체가 3-[3-6-벤조일옥시-3-시아노-2-피리딜옥시카르보닐)벤조일]-1-에톡시메틸-5-플루오로우라실인 암의 치료방법.6. The 5-fluorouracil derivative according to claim 5, wherein the 5-fluorouracil derivative is 3- [3-6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl) benzoyl] -1-ethoxymethyl-5-fluorouracil. Method of treatment of phosphorus cancer. 암 치료용 조성물을 제조하기 위한 하기 일반식(I)로 표시되는 5-플루오로우라실 유도체의 용도.Use of a 5-fluorouracil derivative represented by the following general formula (I) for preparing a composition for treating cancer. [상기 식중, Ra는 C1~C6알콕시메틸기이다].[Wherein R a is a C 1 to C 6 alkoxymethyl group]. 제7항에 있어서, 5-플루오로우라실 유도체가 3-[3-(6-벤조일옥시-3-시아노-2-피리딜옥시카르보닐)벤조일]-1-에톡시메틸-5-플루오로우라실인 암 치료용 조성물을 제조하기 위한 5-플루오로우라실 유도체의 용도.The method of claim 7, wherein the 5-fluorouracil derivative is 3- [3- (6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl) benzoyl] -1-ethoxymethyl-5-fluoro Use of a 5-fluorouracil derivative for preparing a composition for treating cancer that is uracil. 암을 치료하기 위한 하기 일반식(1)로 표시되는 5-플루오로우라실 유도체의 용도.Use of the 5-fluorouracil derivative represented by following General formula (1) for treating cancer. [상기 식중, Ra는 C1~C6알콕시메틸기이다].[Wherein R a is a C 1 to C 6 alkoxymethyl group]. 제9항에 있어서, 5-플루오로우라실 유도체가 3-[3-(6-벤조일옥시-3-시아노-2-피리딜옥시카르보닐)벤조일]-1-에톡시메틸-5-플루오로우라실인 암을 치료하기 위한 5-플루오로우라실 유도체의 용도.10. The process of claim 9, wherein the 5-fluorouracil derivative is 3- [3- (6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl) benzoyl] -1-ethoxymethyl-5-fluoro Use of 5-fluorouracil derivatives for treating cancer that is uracil. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019870006895A 1986-07-25 1987-07-01 5-fluorouracil depivatives KR950011394B1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP17646486 1986-07-25
JP176464/1986 1986-07-25
JP86-176464 1986-07-25
JP181027/1986 1986-07-30
JP86-181072 1986-07-30
JP61181027A JPS63301880A (en) 1985-09-03 1986-07-30 5-fluorouracil derivative
JP34161/1987 1987-02-17
JP62034161A JPS63201127A (en) 1987-02-17 1987-02-17 Carcinostatic agent containing 5-fluorouracil derivative
JP87-34161 1987-02-17

Publications (2)

Publication Number Publication Date
KR880001630A true KR880001630A (en) 1988-04-25
KR950011394B1 KR950011394B1 (en) 1995-10-02

Family

ID=27288338

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019870002961A KR950009857B1 (en) 1986-07-25 1987-03-30 Process for preparing 5-fluorouracil derivatives
KR1019870006895A KR950011394B1 (en) 1986-07-25 1987-07-01 5-fluorouracil depivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1019870002961A KR950009857B1 (en) 1986-07-25 1987-03-30 Process for preparing 5-fluorouracil derivatives

Country Status (10)

Country Link
KR (2) KR950009857B1 (en)
CH (1) CH671578A5 (en)
DE (1) DE3709699C2 (en)
DK (1) DK169520B1 (en)
ES (1) ES2004904A6 (en)
FR (1) FR2605006B1 (en)
GB (1) GB2192880B (en)
IT (1) IT1207785B (en)
NL (1) NL194043C (en)
SE (1) SE464303B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4864021A (en) * 1984-10-30 1989-09-05 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
WO1990007334A1 (en) 1989-01-05 1990-07-12 Otsuka Pharmaceutical Co., Ltd. Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer
WO1992001453A1 (en) * 1990-07-19 1992-02-06 Otsuka Pharmaceutical Co., Ltd. Solid preparation
PL2495243T3 (en) * 2009-10-27 2017-07-31 Delta-Fly Pharma, Inc. Novel 5-fluorouracil derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0180897B1 (en) * 1984-10-30 1991-08-07 Otsuka Pharmaceutical Co., Ltd. 5-fluorouracil derivatives
JPS61114739A (en) * 1984-11-08 1986-06-02 Mitsubishi Rayon Co Ltd Preparation of catalyst for preparing unsaturated carboxylic acid

Also Published As

Publication number Publication date
CH671578A5 (en) 1989-09-15
GB2192880A (en) 1988-01-27
FR2605006A1 (en) 1988-04-15
DK133387D0 (en) 1987-03-16
DE3709699A1 (en) 1988-02-04
DK169520B1 (en) 1994-11-21
KR950009857B1 (en) 1995-08-29
IT1207785B (en) 1989-06-01
SE464303B (en) 1991-04-08
DK133387A (en) 1988-01-26
SE8701118D0 (en) 1987-03-18
GB2192880B (en) 1990-05-09
NL8700742A (en) 1988-02-16
ES2004904A6 (en) 1989-02-16
SE8701118L (en) 1988-01-26
FR2605006B1 (en) 1990-01-12
NL194043C (en) 2001-05-03
KR950011394B1 (en) 1995-10-02
IT8705150A0 (en) 1987-03-30
KR880001635A (en) 1988-04-25
DE3709699C2 (en) 1996-09-05
NL194043B (en) 2001-01-02
GB8706972D0 (en) 1987-04-29

Similar Documents

Publication Publication Date Title
HUP9600448A2 (en) Naphthyl compounds, pharmaceutical compositions containing them, process for producing them, their intermediates and their use
KR900014367A (en) Pyrrolidine derivatives
KR920008026A (en) Isoquinolinone derivatives or nontoxic acid addition salts thereof or hydrates thereof, methods for preparing the same, and pharmaceutical compositions comprising the same
ATE219363T1 (en) SOLUBLE PRODRUGS OF PACLITAXEL
UA41446C2 (en) Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
KR890002060A (en) Oxazolidinone Compound
KR890000470A (en) 2,2-dimethylchroman-3-ol derivative, preparation method thereof, and pharmaceutical composition containing same
KR940005274A (en) Sjoegren Syndrome Treatment
KR910007867A (en) Phenotanolamine Compound
KR840006492A (en) Process for preparing platinum-diamine complex
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
KR890006625A (en) 2,2-dimethylchromen derivative, preparation method thereof and pharmaceutical composition containing the same
KR920004387A (en) 4-substituted dihydropyrido [4,3-d] pyrimidines as topical anti-inflammatory agents for the treatment of analgesics and skin diseases
KR910009259A (en) Pyrimidone derivatives and homologues for the treatment of asthma or certain skin diseases
KR880001630A (en) 5-fluorouracil derivatives and uses thereof
KR890012942A (en) 5-substituted ornithine derivatives
KR880004810A (en) Peptic Ulcer Treatment
KR850006429A (en) New cyanoimidazole nucleoside derivatives and preparation method thereof
KR880013938A (en) Active compounds
KR880009656A (en) Treatment or prophylaxis of local periodontal disease
GB1354451A (en) Halogen-substituted phenyl-alkylamines and their derivatives
KR830009776A (en) Induction of Cell Protection
KR910011258A (en) How to Treat Glaucoma
KR890017363A (en) Strobiliurin derivatives, their preparation and uses
KR900701273A (en) Anti-Ecstatic Ergoline Derivatives

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050926

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee